查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493340

美国mRNA合成原料市场规模、份额、趋势分析报告：按类型、按应用、按最终用途、细分市场预测，2024-2030年

U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report, By Type (Capping Agents, Nucleotides, Plasmid DNA), By Application (Vaccine, Therapeutics), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国mRNA合成原料市场成长及趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，美国mRNA合成原料市场规模将达到9.762亿美元，2024年至2030年复合年增长率为2.93%。

推动市场的关键因素包括学术界和工业界对 mRNA 技术兴趣的增加、mRNA 疫苗的优越性以及 mRNA 研究资金的增加。

随着针对 COVID-19 疾病的 mRNA 疫苗的开发和普及，2020 年是 mRNA 技术平台的分水岭。截至年终，5家上市mRNA平台公司市值超过150亿美元。 2021 年 8 月，该市值约为 3,000 亿美元。最近，受 mRNA COVID-19 疫苗成功吸引的重大投资正在推动治疗多种疾病的药物的开发。该市场是由临床试验的快速增加和干细胞治疗的使用增加所推动的。

此外，随着对 mRNA 疫苗和药品的需求增加，主要企业正在投资新设施以加强其管道和生产​​能力。例如，2021年6月，赛诺菲宣布投资约4.728亿美元建立mRNA卓越中心，以加速下一代疫苗的开发和交付。同样在2022年6月，赢创与美国政府合作，投资2.2亿美元在美国建立一个新的脂质生产设施，用于基于mRNA的疗法。因此，专注于 mRNA 研究的领先公司增加资金和投资预计将推动市场成长。

然而，mRNA 合成的原料是 mRNA 治疗药物合成中最昂贵的成分。此外，由于这些原材料是新的，而且供应链并不多元化，因此提供这些关键原材料的供应商数量有限。例如，生产 1 亿剂 mRNA-1273 和 BNT162b2 预计分别需要 2.7 亿美元和 1.271 亿美元，阻碍了市场成长。

美国mRNA合成原料市场报告亮点

  • 封盖剂在各类型细分市场中均占据主导地位，2023 年销售份额最大，为 41.02%。封端剂可作为结合分子和稳定剂，以防止空间位阻和聚集。因此，封端剂在 mRNA 合成中的这些关键功能正在推动这一领域的发展。
  • 按应用划分，疫苗製造占据最大的收益市场占有率， 2023年为83.86%。癌症、呼吸道疾病、心臟疾病和 CKD 等慢性疾病的盛行率不断上升，促使科学家利用 mRNA 技术来发现新的、更有效的疫苗。
  • 按最终用途划分，生物製药和製药公司在这一领域占据主导地位，2023 年收益占有率为 49.56%，预计在预测期内将以最高复合年增长率增长。这是因为市场新兴企业已经加入多个联盟，以增强其 mRNA 合成原料的供应。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国mRNA合成原料市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场问题分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章美国mRNA合成原料市场：类型预估及趋势分析

  • 类型细分仪表板
  • 美国mRNA合成原料市场类型波动分析
  • 2018-2030年美国mRNA合成原料市场规模及趋势分析（依类型）
  • 封端剂
  • 核苷酸
  • 质体DNA
  • 酵素
  • 其他的

第五章美国mRNA合成原料市场：应用预估及趋势分析

  • 使用细分仪表板
  • 美国mRNA合成原料市场应用变化分析
  • 2018-2030年美国mRNA合成原料市场规模及趋势分析（依应用）
  • 疫苗生产
  • 治疗药物製造
  • 其他的

第六章美国mRNA合成原料市场：最终用途估算及趋势分析

  • 最终用途细分仪表板
  • 美国mRNA合成原料市场最终用途变化分析
  • 2018-2030年美国mRNA合成原料市场规模及趋势分析（依最终用途）
  • 生物製药和製药公司
  • 合约研究官（CRO）和首席行销长（CMO）
  • 学术研究所

第七章 竞争格局

  • 公司分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/名单
    • F. Hoffmann-La Roche Ltd.
    • Jena Bioscience GmbH
    • Merck KGaA
    • Yeasen Biotechnology（Shanghai）Co., Ltd
    • BOC Sciences
    • Thermo Fisher Scientific, Inc.
    • Maravai LifeSciences
    • New England Biolabs
    • Creative Biogene
    • HONGENE
    • Evonik Industries AG
    • GENEVANT SCIENCES CORPORATION
Product Code: GVR-4-68040-283-7

U.S. mRNA Synthesis Raw Materials Market Growth & Trends:

The U.S. mRNA synthesis raw materials market size is anticipated to reach USD 976.2 million by 2030 and is growing at a CAGR of 2.93% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the market include growing academic & industrial interest in mRNA technology, advantages of mRNA vaccines, and increasing funding for mRNA research.

The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.

Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.

However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.

U.S. mRNA Synthesis Raw Materials Market Report Highlights:

  • Capping agents dominated the type segment with the largest revenue share of 41.02% in 2023. Capping agents function as binding molecules or stabilizers, preventing steric hindrance or agglomeration. Hence, these key functions of capping agents in mRNA synthesis are driving the segment
  • Based on the application, vaccine production held the largest revenue market share of 83.86% in 2023. The rising prevalence of chronic diseases, such as cancer, respiratory disorders, cardiac diseases, CKD, and many others, is encouraging scientists to discover novel as well as more effective vaccines using mRNA technology
  • Based on end-use, biopharmaceutical & pharmaceutical companies dominated the segment with a revenue share of 49.56% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the emerging companies in the market entering several collaborations to enhance their mRNA synthesis raw materials offerings

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Type Segment
    • 1.1.2. Application Segment
    • 1.1.3. End-use Segment
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Primary Research
  • 1.5. Information or Data Analysis:
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. mRNA Synthesis Raw Material Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing academic & industrial interest in mRNA technology
      • 3.2.1.2. Advantages of mRNA vaccines
      • 3.2.1.3. Increasing funding for mRNA research
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
      • 3.2.2.2. High cost of mRNA synthesis raw materials
    • 3.2.3. Market Challenge Analysis
      • 3.2.3.1. Lack of long-lasting and affordable manufacturing processes
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. mRNA Synthesis Raw Material Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
  • 4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Capping Agents
    • 4.4.1. Capping Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Nucleotides
    • 4.5.1. Nucleotides Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Plasmid DNA
    • 4.6.1. Plasmid DNA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Enzymes
    • 4.7.1. Enzymes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. Polymerase
      • 4.7.2.1. Polymerase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. RNase Inhibitor
      • 4.7.3.1. RNase Inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.4. DNase
      • 4.7.4.1. DNase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.5. Others
      • 4.7.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. mRNA Synthesis Raw Material Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
  • 5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Vaccine Production
    • 5.4.1. Vaccine Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutics Production
    • 5.5.1. Therapeutics Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. mRNA Synthesis Raw Material Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Segment Dashboard
  • 6.2. U.S. mRNA Synthesis Raw Materials Market End-use Movement Analysis
  • 6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Biopharmaceutical & Pharmaceutical Companies
    • 6.4.1. Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Company Profiles/Listing
    • 7.4.1. F. Hoffmann-La Roche Ltd.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Jena Bioscience GmbH
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Merck KGaA
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. BOC Sciences
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Thermo Fisher Scientific, Inc.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Maravai LifeSciences
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. New England Biolabs
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Creative Biogene
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. HONGENE
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Evonik Industries AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GENEVANT SCIENCES CORPORATION
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. mRNA synthesis raw materials market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. mRNA synthesis raw materials market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. mRNA synthesis raw materials market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 Key companies undergoing expansions
  • Table 7 Key companies undergoing acquisitions
  • Table 8 Key companies undergoing collaborations
  • Table 9 Key companies launching new products/services
  • Table 10 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. mRNA synthesis raw materials market: market outlook
  • Fig. 7 U.S. mRNA synthesis raw materials competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 U.S. mRNA synthesis raw materials market driver impact
  • Fig. 10 U.S. mRNA synthesis raw materials market restraint impact: Type & services movement analysis
  • Fig. 11 U.S. mRNA synthesis raw materials market: Type outlook and key takeaways
  • Fig. 12 Capping agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Nucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Plasmid DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Polymerase market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 RNase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 DNase materials market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 21 U.S. mRNA synthesis raw materials market: Application movement analysis
  • Fig. 22 U.S. mRNA synthesis raw materials market: Application outlook and key takeaways
  • Fig. 23 Vaccine production market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Therapeutics production market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others application market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. mRNA synthesis raw materials market: End-use movement analysis
  • Fig. 27 U.S. mRNA synthesis raw materials market: End-use outlook and key takeaways
  • Fig. 28 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 CROs CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Market share of key market players - U.S. mRNA synthesis raw materials market